Introduction
Recent developments in genetics research, particularly genome-wide association studies (GWAS), have greatly improved our understanding of the genetic architecture of complex disorders such as schizophrenia. The additive contributions of hundreds or thousands of polymorphisms, regulating different biochemical pathways related to the phenotype, determine the genetic liability to complex disorders (1) . It has been established that schizophrenia is highly polygenic, with many common genetic variants contributing to the risk to the disease. In the latest meta-analysis of GWAS for schizophrenia (2) , 108 independent regions associated with the disease were identified.
Risk prediction remains a primary focus of genetic studies. In schizophrenia, this has been largely based on family history, but with the progress in GWAS, an increasing number of susceptibility variants has been found that contribute to risk prediction (3) . However, each genetic marker individually explains only a tiny proportion of the genetic variation with insignificant predictive power (4) . For this reason, methods have been developed to examine disorder prediction by genetic variants en masse, via summarizing variation across many nominally associated loci into quantitative scores that are tested in independent samples (5) . One such approach is the generation of polygenic risk scores (PRS), which represents a promising technique for predicting risk (6, 7) .
PRS have been successfully associated with schizophrenia and as the size of the discovery sample increases, their accuracy and predictive power improve. For example, from explaining ~3% of the variance of a case-control sample in 2009 (5) they now explain ~18% (2) . To establish whether PRS may be a useful tool for risk prediction, replication and further studies in independent samples are necessary.
Importantly, these samples should represent the "typical" patients we see in the clinical practice rather than the severe end of the phenotype that is more easily identified and recruited for research (8) . For this reason, in a sample of patients recruited during a first episode of psychosis (FEP) and ancestry matched controls from South London, we measured the ability of PRS to discriminate cases from controls and among cases to discriminate schizophrenia from other psychoses.
Methods and Materials

Sample description
Participants were recruited as part of the Biomedical Research Centre for Mental Health (BRC-MH) Genetics and Psychosis (GAP) study (9) . The study systematically recruited patients aged 18 to 65 years who presented to adult psychiatric services in the South London and Maudsley NHS Foundation Mental Health Trust between December 2005 and October 2011 with a first episode of non-organic psychosis (ICD-10 codes: F20-F29 and F30-F33) (10) and unaffected controls. This is a multi-ethnic sample, reflecting the demographics of the area. Clinical diagnoses of cases were validated using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview (11) and controls were screened with the Psychosis Screening Questionnaire (12) . Cases meeting criteria for organic psychosis, intellectual disability (IQ<70), or with transient psychosis (less than 7 days of symptoms) and controls who reported previous diagnosis of psychosis or had a first degree relative with psychosis were excluded.
As the diagnostic evaluation of FEP patients is difficult due to the short history of illness and variable symptomatology seen (13) , the following diagnostic approaches were used: (1) Consensus Diagnoses based on discussions between experienced clinicians who interviewed the patients using the SCAN to collect symptoms characteristics, frequency and duration over the four weeks preceding the assessment; utilizing the SCAN, Present State Examination Data and applying the Operational Criteria Checklists (OPCRIT) computerized algorithms (14) to obtain diagnoses according to (2) DSM-IV and (3) ICD-10 classification systems, and (4) clinical diagnoses made by the treating psychiatrists collected retrospectively from the electronic medical records of the patients.
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This study was granted ethical approval by the South London and Maudsley and Institute of Psychiatry Local Research Ethics Committee. All individuals included gave informed written consent to be assessed at baseline, to be re-contacted at follow-up; they gave us permission to access their clinical records and to publish data originating from the study.
For replication of the utility of PRS to discriminate between schizophrenia and other psychoses, a second sample recruited from the same geographical area -the IMPACT study (Improving Physical Health and Reducing Substance Use in Psychosis) (15) -was used. This comprises 280 patients with chronic psychosis (mean illness duration 16 years) who participated in a Randomised Controlled Trial (RCT) of a psychosocial health promotion intervention. Diagnoses were extracted from the documented ICD-10 diagnosis in the clinical notes at the time of recruitment (16) . As this was a case only sample, PRS from IMPACT were compared with controls from the GAP sample. Both samples were genotyped on the same array and genotypic data was processed and analysed together.
As the GAP sample included only 70 African-European controls, we obtained a second sample of subSahara African ancestry controls collected from the same geographical area for the South London Ethnicity and Stroke Study (SLESS) (17) . The controls were recruited by random sampling of general practitioner lists from South London and this data is available as part of a collaboration between the BRC for Mental Health and the GSTT BRC (detailed description of this cohort in the supplement).
Genotyping procedures DNA was extracted from blood or cheek swabs (80 and 20 % of the GAP sample respectively). When several extractions for the same individual were performed, we used DNA from blood. The samples were genotyped at the SLaM/IoPPN BRC Genomics laboratory on the Illumina HumanCore Exome
BeadChip. This array provides genetic data for identified genome-wide significant single nucleotide polymorphisms (SNPs), a cost-effective genome-wide coverage of 265,000 highly-informative tag SNPs, plus 245,000 rare, predicted deleterious variants. The latter were excluded from our analysis. Genotypes were processed using the GenomeStudio Analysis software v2011.1 (Illumina Inc).
Quality Control (QC) included exclusion of SNPs with Minor Allele Frequency (MAF) <1%, SNPs and individuals with genotypic failure >1%, SNPs with Hardy Weinberg Equilibrium p<10 -5 in controls, mismatch between recorded and genotypic sex, and related individuals. Cryptic relatedness and duplicated samples were identified with pairwise identity by descent method (pi-hat>0.1875).
Imputation was performed with IMPUTE2 (18) based on the 1000 Genomes phase 3 reference panel (19) , using haplotypes from all the ancestral populations (20) . The imputed markers underwent a second stage of QC to exclude SNPs that were missing in more than 5% of individuals or had imputation information score (INFO) <0.8. QC was performed with PLINK 1.9; https://www.cog-genomics.org/plink2
(21).
The SLESS sample was genotyped using the Illumina Multi-Ethnic Genotyping Array (MEGA), a multiethnic platform with >1.7 million markers; http://www.illumina.com/products/infinium-multi-ethnicglobal-array.html. After repeating the above QC procedures, we merged the two samples using only the markers that had been genotyped in both arrays. We excluded any related individuals between the two datasets. We excluded any markers that differed between the two African control groups (detailed QC methods can be found in the Supplementary materials).
Calculation of polygenic risk scores
We used the latest PGC2 schizophrenia meta-analysis (2) as discovery sample, to calculate PRS for each individual in our sample as the weighted sum of the risk alleles they carried. Sample relatedness between the GAP data and PGC2 was tested using the GWAS data. We identified that 80 individuals were already included in PGC2 as part of the WTCCC2 consortium (22); hence, we used the PGC2 leaveone-out discovery dataset, excluding the WTCCC2 sample. To use informative and independent markers, we selected SNPs with MAF >10% and INFO >0.9, according to the PGC2 protocol, and we included only one SNP from the MHC complex LD region on chromosome 6 (hg19; chr6:27-33Mb).
Population stratification was corrected with Principal Component Analysis (PCA) using EIGENSTRAT (23).
Two subsamples were selected for further analysis based on the loadings on the first 2 principal components (PCs), one with European only ancestry and one with African ancestry (combining African and African-Caribbean origin). To further correct for stratification, we repeated PCA in each of the two subsamples separately and we retained 10 PCs for each, which were used as covariates in the PRS analyses.
We performed clumping separately in the European and African sub-samples by retaining the SNP with the smallest p-value from each linkage disequilibrium (LD) block (excluding SNPs with r 2 >0.1 in 250 kb windows). Each allele was weighted by the logarithm of the odds ratio (OR) as estimated in the PGC2 study. Ten different PRS, using subsets of the total SNPs based on different p-value thresholds for the association with schizophrenia in the discovery PGC sample, were computed and were compared for the best discrimination between cases and controls. To construct PRS, we used the Polygenic Risk Score software (PRSice) (24) .
Statistical analysis
Association of PRS with case-control status was performed with logistic regression and Nagelkerke's pseudo-R 2 was calculated to measure the proportion of variance explained. To estimate heritability (i.e.
variance explained at the liability scale) assuming a liability-threshold model, a lifetime risk of 1% for psychosis and 0.72% for schizophrenia (25) , and adjusting for case-control ascertainment, we used the GEnetic Analysis Repository software (http://sourceforge.net/p/gbchen/wiki/GEAR/; Supplemental Table S1 ). For each analysis we estimated and analyzed PRS at 10 different levels of significance at the discovery sample. To correct for multiple hypothesis testing in each sample (European FEP, African FEP,
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European chronic psychosis), we estimated the equivalent number of effective tests using the correlation matrix of PRS at the 10 P-value thresholds (http://gump.qimr.edu.au/general/daleN/matSpD/) and performed Bonferroni correction on the sum of effective tests across the three samples. The effective number of independent variables were 5, 6.4, and 5.3 respectively and the significance threshold required to keep Type I error rate at 5% was 0.003.
To evaluate the specificity of PRS to schizophrenia, we divided cases according to each diagnostic approach (consensus, OPCRIT/DSM, OPCRIT/ICD, clinical) into two diagnostic categories: (1) schizophrenia, and (2) other psychoses, including delusional disorder, acute and transient psychotic disorder, schizoaffective disorder, other nonorganic psychotic disorder, bipolar disorder and psychotic depression. We explored standardized mean differences (SMD) of PRS between the cases stratified in the two diagnostic categories and controls (each diagnostic category was compared with all the controls) and we compared with logistic regression PRS between cases who had met criteria for schizophrenia with at least one of the 4 diagnostic approaches and cases with any other psychosis.
To better visualize the effect of PRS on the risk of psychosis, we estimated case-control odds ratio (OR) and 95% confidence intervals (CI) dividing our sample in quintiles by PRS. To be able to compare our estimates with the outcomes of previous studies (2, 26) and to adjust for oversampling of controls approximating a prevalence of psychosis of 0.72% (25), we employed a simulation method to extract deciles from our observed data. Detailed statistical methods are presented in the Supplement.
Results
Genotyping and quality control
From quality control procedures, 710 individuals (445 cases with first episode psychosis and 265 controls) and 290,871 genotyped markers with MAF >1% were available for analysis for the GAP study 9 and 248 cases for IMPACT. Following imputation 5.2x10 6 variants with INFO score > 0.8 were identified, reduced with clumping to 56,059 independent variants for PRS analysis. Gender, DNA origin, age, and ethnic distribution of cases and controls are presented in Table 1 . The GAP sample gender, ethnicity and age distribution well represent a first episode psychosis adult population from the study geographical area as indicated by previously published studies looking at this patient group (27) . After identifying the two main ethnic groups in the GAP study (Supplemental Figure S2) Polygenic prediction of case-control status
In the overall GAP sample the best discrimination of case-control status by the PRS was achieved with the inclusion of all the independent markers following clumping (65,479), which explained 3.6% of the variance (Nagelkerke's pseudo-R 2 ; p =10 -5 ). When we stratified our analysis by the two main ethnic groups in the GAP study, we observed that PRS explained 9.4% of the variance in individuals of European ancestry (5.2% on the liability scale, p =9.5*10 Table S2 ). The barplots of variance explained by PRS in Europeans and Africans at 10 p-value significance thresholds (P T ) in the discovery sample are presented in Figure 1 .
In the GAP European subsample, cases had on average higher adjusted PRS than controls, with SMD of 0.54, following correction for population stratification. The density distributions of PRS were partially overlapping (Figure 2 ), demonstrating low discriminative power for first episode psychosis (AUC = 0.65).
In European chronic cases from the IMPACT sample the optimal case-control discrimination by PRS was also achieved at P T <0.1, explaining 6% of the variance (p =10 -4 ). We observed that chronic cases had lower PRS than FEP cases, but the difference was not significant.
Discrimination between schizophrenia and other psychoses
In Figure 3 we present the SMD of PRS between cases divided into two diagnostic categories (those who had met criteria for schizophrenia with at least one of the 4 diagnostic approaches described previously, and those who had not) and controls. Diagnosis with at least one of the four diagnostic approaches was available in 151 European and 177 African FEP cases and 132 chronic European cases. We observed that both schizophrenia and other psychoses groups in all three samples had higher PRS than their corresponding controls and that, in European samples, individuals with a diagnosis of schizophrenia had higher PRS than other psychoses.
In the GAP FEP European subsample we repeated the case-control analysis stratifying cases by diagnosis and observed that PRS was more predictive for cases with schizophrenia (R 2 =16.3%, p=3.7*10 -7
) than for cases with other psychoses (R 2 =2.7%, p=0.03). In a case-only analysis, comparing those with at least one diagnosis of schizophrenia in any of the four diagnostic approaches (n=86) versus those FEP cases who never met diagnostic criteria for schizophrenia (n=65), we found that schizophrenia cases had higher PRS than cases with other psychoses (Nagelkerke's R 2 =9.2%, p=0.002).
In the IMPACT chronic psychosis sample, stratification by the recorded ICD-10 diagnosis to schizophrenia and other psychoses resulted, similar to the findings in FEP, in higher PRS for cases with a diagnosis of schizophrenia compared to cases with any other psychoses (R (Figure 4) . Following simulation to a larger sample with the same characteristics and using the lowest PRS group as baseline, this translates to an OR of 7.7 when comparing the top and bottom deciles (Supplemental Figure S9) .
Discussion
Polygenic discrimination of case-control status and risk prediction in first episode psychosis
The dual goals of schizophrenia genetics are to improve our understanding of the biology of the disorder with the hope of thereby developing novel therapeutic agents, and to identify individuals at elevated risk before disease onset, aiming to expedite early diagnosis (28) . A polygenic theory of schizophrenia was first hypothesized in 1967 (29) At present, the discriminative accuracy of PRS for schizophrenia is not sufficient for use in population screening to identify individuals at high risk for the disease, and indeed, PRS may never be powerful enough for screening (2, 30) . However, PRS explains a substantial amount of the variance of schizophrenia in Europeans, probably more than any traditional risk factor. In our samples, the OR for psychosis of the high versus the low exposure group is higher for PRS (7. FEP provides an opportunity to test PRS against clinical outcomes beyond case status. In our sample, only 57% of FEP cases obtained a diagnosis of schizophrenia while the remainder had bipolar disorder, psychotic depression, acute or unspecified psychotic disorder. We found significant discrimination between schizophrenia and other psychoses within our FEP cases of European descent (9.2% of variance explained). Previous studies of the schizophrenia PGC 1 PRS found it to be higher in patients with a broad spectrum of psychotic disorders versus controls (35, 36) , but discrimination between schizophrenia and other psychotic disorders was non-or marginally significant. The improvement of discriminative accuracy seen in our sample is explained by the increased predictive power of PRS constructed from the newer PGC2 dataset. This supports the utility of further increasing the global schizophrenia sample size with genome-wide genotyping.
It is noteworthy that the discriminative accuracy of PRS was higher for schizophrenia cases in our FEP cohort than for our group of (older) cases with chronic schizophrenia, identified from a clinical trial cohort. We cannot draw definite conclusions as the sample sizes are small; however, this finding is not unexpected. Patients with an average of 16 years of psychotic illness who maintain capacity to consent and participate in an intervention study are most probably not at the extreme end of the continuum in terms of illness severity. Furthermore, this observation supports the utility of PRS in early stages of the disease, as this design may be better at including patients with potentially more severe illness progression. Moreover, when we stratified chronic cases by diagnosis, we observed that, in the chronic group, PRS did not discriminate other (non-schizophrenia) psychoses from controls. It may be, that if someone has maintained a non-schizophrenic psychotic disorder for 16 years, they are highly unlikely to develop schizophrenia later. However, these observations of PRS prediction in chronic versus FEP cases will require replication in independent samples.
Ethnic differences
One of our striking findings was the substantial difference in PRS discrimination of case-control status between individuals from European and African ancestry. It is remarkable that PRS explains as much as 9.4% of the variance in Europeans while it has low discriminative ability in Africans (1.1% of the variance explained in the joint analysis of GAP sample with SLESS controls). The PGC2 discovery data included 49
European, 3 Asian, and no African-ancestry samples (2), while it is well established that Africans have higher genetic diversity and consequently shorter LD blocks (37) , which is particularly relevant as most associated SNPs are genetic markers in LD with the unrecognized causal variants (38) .
Other causes for this difference should be considered. It is already suggested that schizophrenia is a constellation of different disorders (39, 40) . There is always the possibility that different genetic and biological pathways are involved. However, previous work shows that many schizophrenia risk alleles 14 are shared across ethnic groups, predating African-European divergence (41, 42 (45) . All of these factors may confer lower discriminative power.
Limitations
The predictive ability of PRS depends, among other factors, on the number of markers in the genotyping panel (7), which affects the accuracy of the simulated SNP calls. The array we used provided an efficient genome-wide coverage for our European sample, but not for the Africans as discussed previously, and genotyping with denser arrays may be necessary to measure the predictive power of PRS in nonEuropean populations. Although our study was sufficient to analyze European and Africans, we did not have enough samples for separate analysis of the other ethnic groups, especially as we expected lower prediction of PRS, and insufficient evidence exists at present for combined analyses across ethnicities (46) . In our total sample, PRS explained only 3.6% of the variance in case-control status prediction, capturing most probably genetic signal mainly from the Europeans.
Conclusions -Suggestions for further research
The continuing effort to increase the global sample size has resulted in the discriminative ability of the PRS improving and, as we have shown, the predictive power is sufficient to detect genetic signal in moderate to small samples. Genotyping of large samples from different ethnic groups would be important to be able to generalize the findings to non-European populations. Ideally, this should include samples collected at the country of origin, to avoid potential confounders, such as migration and other socioeconomic differences that may affect case-control status (43) .
To explore the clinical importance of the association of PRS with psychosis and to better understand the biology of the genetic predisposition to psychosis by common variants, further research in the field should go beyond the association with case-control status. A non-exclusive list of important research questions include the association of PRS with: (1) severity or course of illness, (2) conversion of individuals with prodromal symptoms to psychosis, (3) response to treatment, (4) endophenotypes and symptom profiles, and (5) physical health and quality of life. 
